Drug
Avapritinib
Avapritinib: highest development phase Post-Market, developed by Blueprint Medicines, United Therapeutics. 10 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Blueprint Medicines, United Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| Avapritinib NCT04825574 | Post-Market | Gastrointestinal Stromal Tumors |
| Avapritinib NCT06748001 | Post-Market | Mastocytosis, Systemic |
| avapritinib NCT03465722 | Phase 3 | GIST |
| Avapritinib NCT03731260 | Phase 2 | Indolent Systemic Mastocytosis |
| Avapritinib NCT03580655 | Phase 2 | Advanced Systemic Mastocytosis |
| avapritinib NCT04773782 | Phase 1/2 | Solid Tumor, Unspecified, Child |
| Avapritinib NCT06327685 | Phase 1 | Systemic Mastocytosis With an Associated Hematologic Neoplasm |
| Avapritinib NCT02561988 | Phase 1 | Aggressive Systemic Mastocytosis |
| Avapritinib NCT02508532 | Phase 1 | Gastrointestinal Stromal Tumors (GIST) |
| Avapritinib NCT04908176 | Phase 1 | Gastrointestinal Stromal Tumors |
Latest
No recent events.
Follow Avapritinib on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.